Profile data is unavailable for this security.
About the company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-35.52m
- Incorporated2011
- Employees17.00
- LocationTempest Therapeutics Inc2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE 94005United StatesUSA
- Phone+1 (415) 798-8589
- Fax+1 (302) 655-5049
- Websitehttps://www.tempesttx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlycoMimetics Inc | 10.00k | -39.74m | 20.63m | 35.00 | -- | 1.81 | -- | 2,063.49 | -0.6165 | -0.6165 | 0.0002 | 0.1764 | 0.0003 | -- | 0.0836 | 285.71 | -115.34 | -43.60 | -136.58 | -47.82 | -- | -- | -397,350.50 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Pieris Pharmaceuticals Inc | 1.35m | -15.95m | 21.04m | 46.00 | -- | 1.29 | -- | 15.56 | -12.61 | -12.61 | 1.06 | 12.32 | 0.0338 | -- | 1.91 | 29,391.30 | -39.93 | -28.41 | -68.21 | -39.69 | -- | -- | -1,179.96 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.44m | 21.12m | 4.00 | -- | 8.18 | -- | -- | -1.09 | -1.09 | 0.00 | 0.1589 | 0.00 | -- | -- | 0.00 | -250.15 | -- | -498.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 9.78m | -65.09m | 21.69m | 100.00 | -- | 0.3012 | -- | 2.22 | -1.71 | -1.71 | 0.2567 | 1.88 | 0.0687 | -- | -- | 97,790.00 | -45.72 | -48.32 | -52.52 | -54.03 | -- | -- | -665.56 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Cocrystal Pharma Inc | 0.00 | -18.70m | 21.87m | 12.00 | -- | 1.72 | -- | -- | -1.84 | -1.84 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -76.57 | -50.94 | -83.17 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Aeon Biopharma Inc | 0.00 | -350.57m | 22.09m | 5.00 | -- | -- | -- | -- | -9.61 | -9.61 | 0.00 | -0.8106 | 0.00 | -- | -- | 0.00 | -3,242.54 | -- | -- | -- | -- | -- | -- | -- | -- | 2.94 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.57m | 22.31m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Pulmatrix Inc | 10.01m | -9.66m | 22.32m | 22.00 | -- | 2.04 | -- | 2.23 | -2.64 | -2.64 | 2.74 | 2.99 | 0.4145 | -- | 23.16 | 454,772.70 | -40.00 | -46.91 | -44.64 | -58.12 | -- | -- | -96.51 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Ibio Inc | 175.00k | -14.36m | 22.39m | 16.00 | -- | 1.19 | -- | 127.93 | -3.97 | -6.65 | 0.0307 | 2.06 | 0.0056 | -- | -- | 10,937.50 | -46.17 | -27.69 | -75.53 | -33.13 | -- | -- | -8,204.57 | -1,862.11 | -- | -- | 0.0736 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
| Tempest Therapeutics Inc | 0.00 | -35.52m | 22.53m | 17.00 | -- | 2.07 | -- | -- | -1.57 | -1.57 | 0.00 | 0.4313 | 0.00 | -- | -- | 0.00 | -122.85 | -57.10 | -195.00 | -71.20 | -- | -- | -- | -- | -- | -- | 0.426 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Forte Biosciences Inc | 0.00 | -34.20m | 22.84m | 11.00 | -- | 2.44 | -- | -- | -20.00 | -20.00 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -103.90 | -72.06 | -137.40 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Cadrenal Therapeutics Inc | 0.00 | -7.61m | 23.24m | 4.00 | -- | 5.07 | -- | -- | -7.05 | -7.05 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -108.76 | -- | -125.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Exicure Inc | 500.00k | -4.01m | 23.59m | 6.00 | -- | 15.27 | -- | 47.18 | -2.26 | -2.26 | 0.282 | 0.7112 | 0.0424 | -- | 0.4852 | 83,333.34 | -33.98 | -41.52 | -45.26 | -55.78 | -- | -- | -801.40 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.74m | 23.66m | 25.00 | -- | 0.7023 | -- | -- | -2.51 | -2.51 | 0.00 | 4.05 | 0.00 | -- | -- | 0.00 | -43.08 | -45.97 | -47.69 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 24.70m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Tempest Therapeutics Inc's reporting currency: US Dollar USD
7.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 547.89k | 2.06% |
| Altium Capital Management LPas of 30 Sep 2024 | 545.00k | 2.05% |
| Geode Capital Management LLCas of 30 Sep 2024 | 220.07k | 0.83% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 174.01k | 0.66% |
| FIL Investment Advisors (UK) Ltd.as of 30 Sep 2024 | 129.58k | 0.49% |
| Ikarian Capital LLCas of 30 Sep 2024 | 105.60k | 0.40% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 98.54k | 0.37% |
| GSA Capital Partners LLPas of 30 Sep 2024 | 94.91k | 0.36% |
| Virtu Americas LLCas of 30 Jun 2024 | 62.03k | 0.23% |
| FullCircle Wealth LLCas of 30 Sep 2024 | 62.00k | 0.23% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
